Search Result

Results for "

Diabetic rats

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Aldose Reductase (3) Apoptosis (3) Autophagy (1) Biochemical Assay Reagents (1) Endogenous Metabolite (4) Free Fatty Acid Receptor (2) Glucokinase (1) Glucosidase (3) Insulin Receptor (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) Mitophagy (1) Neuropeptide Y Receptor (2) Opioid Receptor (2) p38 MAPK (1) Phosphodiesterase (PDE) (4) PKC (1) PKG (2) SHP2 (1) SRPK (1) Urotensin Receptor (2) VEGFR (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (8) Endocrinology (4) Inflammation/Immunology (7) Metabolic Disease (22) Neurological Disease (4)

By Targets:

Akt (1)

Aldose Reductase (3)

Apoptosis (3)

Autophagy (1)

Biochemical Assay Reagents (1)

Endogenous Metabolite (4)

Free Fatty Acid Receptor (2)

Glucokinase (1)

Glucosidase (3)

Insulin Receptor (1)

Isotope-Labeled Compounds (1)

Mitochondrial Metabolism (1)

Mitophagy (1)

Neuropeptide Y Receptor (2)

Opioid Receptor (2)

p38 MAPK (1)

Phosphodiesterase (PDE) (4)

PKC (1)

PKG (2)

SHP2 (1)

SRPK (1)

Urotensin Receptor (2)

VEGFR (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (8)

Endocrinology (4)

Inflammation/Immunology (7)

Metabolic Disease (22)

Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116239

Zenarestat	Aldose Reductase	Neurological Disease Metabolic Disease
Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats .

HY-121401A

(−)-Myrtenal (1R)-(−)-Myrtenal; (−)-(1R,5S)-Myrtenal	Akt	Metabolic Disease Cancer
(−)-Myrtenal ((1R)-(−)-Myrtenal) is an orally active terpene with antitumour activity. (−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats .

HY-144289

BMS-820132	Glucokinase	Metabolic Disease
BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC₅₀ of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .

HY-N9363

Corymbiferin	Others	Metabolic Disease
Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .

HY-111327

Valibose	Glucosidase	Metabolic Disease
Valibose is analpha-glucosidaseinhibitor, and ameliorates the metabolic disorder of glucose and lipids and the nephropathy in Streptozotocin (HY-13753)-induced diabetic rats .

HY-N2531

Notoginsenoside Fc	Autophagy	Cardiovascular Disease
Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy .

HY-131542

APPA	Aldose Reductase Apoptosis	Metabolic Disease
APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research .

HY-162325

WJ-39	Aldose Reductase Mitochondrial Metabolism Apoptosis Mitophagy	Metabolic Disease
WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis .

HY-N3015

Bruceine E	Others	Metabolic Disease
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ)-induced diabetic rats at lower dose .

HY-10655

Palosuran 2 Publications Verification ACT-058362	Urotensin Receptor	Cardiovascular Disease
Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC₅₀ of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats .

HY-10655A

Palosuran hydrochloride 2 Publications Verification ACT-058362 hydrochloride	Urotensin Receptor	Cardiovascular Disease
Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC₅₀ of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats .

HY-163005

α-Glucosidase-IN-43	Glucosidase	Metabolic Disease
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC₅₀: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .

HY-151138

α-Glucosidase-IN-16	Glucosidase	Metabolic Disease
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .

HY-145633

Sozinibercept OPT 302; VGX-300	VEGFR	Cardiovascular Disease
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .

HY-W010655

Fasiglifam hemihydrate TAK-875 hemihydrate	Free Fatty Acid Receptor	Metabolic Disease
Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC₅₀ of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .

HY-P1131

M617	Neuropeptide Y Receptor	Cardiovascular Disease
M617 is a selective galanin receptor 1 (GAL1) agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .

HY-100446

NTU281
NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes .

HY-P1131A

M617 TFA	Neuropeptide Y Receptor	Cardiovascular Disease
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .

HY-107384

Asimadoline EMD-61753	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-107384A

Asimadoline hydrochloride EMD-61753 hydrochloride	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) hydrochloride is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline hydrochloride has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline hydrochloride ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-160602

CPL207280	Free Fatty Acid Receptor	Metabolic Disease
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .

HY-139467

PF-04577806	SHP2 PKC	Metabolic Disease
PF-04577806 is a potent, selective and ATP competitive PKC inhibitor. PF-04577806 shows potent inhibitory activity towards PKCα, PKCβI, PKCβII, PKCγ, and PKCθ with IC₅₀s of 2.4 nM, 8.1 nM, 6.9 nM, 45.9 nM, and 29.5 nM, respectively. PF-04577806 can reverse retinal vascular leakage in diabetic rats .

HY-125588

Chromium picolinate 1 Publications Verification Chromium (III) picolinate; Cr(Pic)3	Apoptosis p38 MAPK	Metabolic Disease
Chromium picolinate (Chromium (III) picolinate) is a compound that has oral activity. Chromium picolinate induces apoptosis. Chromium picolinate is the activator of p38 MAPK. Chromium picolinate has antioxidant activity. Chromium picolinate can be used in research on type 2 diabetes .

HY-N1940

β-Anhydroicaritin 1 Publications Verification
β-Anhydroicaritin is isolated from Boswellia carterii Birdware, has important biological and pharmacological effects, such as antiosteoporosis, estrogen regulation and antitumor properties . β-Anhydroicaritin ameliorates the degradation of periodontal tissue and inhibits the synthesis and secretion of TNF-α and MMP-3 in diabetic rats . β-Anhydroicaritin decreases the overproduction of NO, IL-10, TNF-α, MCP-1 and IL-6 in inperitonitis mice. β-Anhydroicaritin inhibits the elevation of intracellular Ca ²⁺, and markedly decreases iNOS protein expression .

HY-P3247

[D-Ala2]-GIP (human)	Insulin Receptor	Neurological Disease Metabolic Disease
[D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc

HY-117661

SPHINX31 4 Publications Verification	SRPK VEGFR	Cardiovascular Disease Cancer
SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC₅₀ of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A₁₆₅a isoform. SPHINX31 can be used to research neovascular eye disease .

HY-P1556

Vasonatrin Peptide (VNP)	PKG	Cardiovascular Disease
Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-P1556A

Vasonatrin Peptide (VNP) (TFA)	PKG	Metabolic Disease
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-W127391

1,2-Dilaurin (Rac)-1,2-Didodecanoylglycerol	Biochemical Assay Reagents	Others
1,2-Dilaurin is a diacylglycerol containing lauric acid at the sn-1 and sn-2 positions. It has been used as an internal standard for the quantification of diglycerides in rat desheathed sciatic nerves. [1] Monomolecular films containing 1,2-dilauroyl-rac-glycerol have been used as substrates to measure surface pressure and the effect of pancreatic procolipase and colipase on porcine pancreatic lipase activity. [2] References: [1]. Zhu, X. and Eichberg, J. 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in the sciatic nerve of streptozotocin-induced diabetic rats. J. Neurochemistry. 55(3), 1087-1090 (1990).[2]. Wieloch, T., Borgstr m, B., Piéroni, G. et al. Porcine trypsinogen and its trypsin-activated form: lipid binding and lipase activation on monomolecular membranes. FEBS Express. 128(2), 217-220 (1981).

HY-B0442C

Vardenafil dihydrochloride	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442

Vardenafil 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442AS

Vardenafil-d5 hydrochloride	Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

1,2-Dilaurin (Rac)-1,2-Didodecanoylglycerol	Biochemical Assay Reagents
1,2-Dilaurin is a diacylglycerol containing lauric acid at the sn-1 and sn-2 positions. It has been used as an internal standard for the quantification of diglycerides in rat desheathed sciatic nerves. [1] Monomolecular films containing 1,2-dilauroyl-rac-glycerol have been used as substrates to measure surface pressure and the effect of pancreatic procolipase and colipase on porcine pancreatic lipase activity. [2] References: [1]. Zhu, X. and Eichberg, J. 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in the sciatic nerve of streptozotocin-induced diabetic rats. J. Neurochemistry. 55(3), 1087-1090 (1990).[2]. Wieloch, T., Borgstr m, B., Piéroni, G. et al. Porcine trypsinogen and its trypsin-activated form: lipid binding and lipase activation on monomolecular membranes. FEBS Express. 128(2), 217-220 (1981).

Cat. No.	Product Name	Target	Research Area

HY-P1131A

M617 TFA	Neuropeptide Y Receptor	Cardiovascular Disease
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .

HY-P3247

[D-Ala2]-GIP (human)	Insulin Receptor	Neurological Disease Metabolic Disease
[D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc

HY-P1556A

Vasonatrin Peptide (VNP) (TFA)	PKG	Metabolic Disease
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-P3206

Serum thymic factor Thymulin; Thymic factor	Peptides	Inflammation/Immunology
Serum thymic factor (Thymulin) is a zinc-dependent immunomodulatory peptide. Serum thymic factor induces hyperalgesia. Serum thymic factor protects rats from Cephaloridine (HY-B2072)-induced nephrotoxicity by inhibiting ERK activation. Serum thymic factor has anti-diabetic, analgesic and anti-inflammatory effects .

HY-P1556

Vasonatrin Peptide (VNP)	PKG	Cardiovascular Disease
Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

Sozinibercept OPT 302; VGX-300	VEGFR	Cardiovascular Disease
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-121401A

(−)-Myrtenal (1R)-(−)-Myrtenal; (−)-(1R,5S)-Myrtenal	Other Monoterpenes Classification of Application Fields Terpenoids Labiatae Source classification Metabolic Disease Erythrina poeppigiana Plants Disease Research Fields	Akt
(−)-Myrtenal ((1R)-(−)-Myrtenal) is an orally active terpene with antitumour activity. (−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats .

HY-N2531

Notoginsenoside Fc	Cardiovascular Disease Triterpenes Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Panax notoginseng Araliaceae	Autophagy
Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy .

HY-N3015

Bruceine E	Simaroubaceae Classification of Application Fields Terpenoids Source classification Metabolic Disease Diterpenoids Plants Disease Research Fields Brucea javanica (L.) Merr.	Others
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ)-induced diabetic rats at lower dose .

HY-N9363

Corymbiferin	Structural Classification other families Xanthones Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Others
Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .

HY-B0442C

Vardenafil dihydrochloride	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442

Vardenafil 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

Cat. No.	Product Name	Chemical Structure

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Diabetic rats

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products